XYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery

Xylyx Bio, a leader in advanced disease models for drug discovery, today announced the launch of specialized contract R&D services that support improved assessment of antifibrotic drug candidate efficacy. Despite ongoing advances, the current drug discovery paradigm is highly inefficient. Read more >>